https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-10-11 / Neuro Oncol 2022 Oct;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-10-11 / Neuro Oncol 2022 Oct;2022-10-11 00:00:002022-10-11 00:00:00Cellular Immunotherapy for Medulloblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-840
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-8402022-09-09 00:00:002024-11-12 09:18:52A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-08 / Cancers (Basel) 2022 Sep;14(18)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-08 / Cancers (Basel) 2022 Sep;14(18)2022-09-08 00:00:002022-09-08 00:00:00Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-07 / Hepatobiliary Pancreat Dis Int 2022 Oct;21(5):440-449
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-07 / Hepatobiliary Pancreat Dis Int 2022 Oct;21(5):440-4492022-09-07 00:00:002022-09-07 00:00:00Current and emerging immunotherapeutic approaches for biliary tract cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-24 / Pharmaceutics 2022 Aug;14(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-24 / Pharmaceutics 2022 Aug;14(9)2022-08-24 00:00:002022-08-24 00:00:00Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-21 / Cancers (Basel) 2022 Aug;14(16)2022-08-21 00:00:002022-08-21 00:00:00Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-10 / Immunol Invest 2022 Nov;51(8):2133-2158
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-10 / Immunol Invest 2022 Nov;51(8):2133-21582022-08-10 00:00:002022-08-10 00:00:00Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-03 / J Control Release 2022 Sep;349:844-875
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-03 / J Control Release 2022 Sep;349:844-8752022-08-03 00:00:002022-08-03 00:00:00Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-01 / Int Immunopharmacol 2022 Sep;110:109016
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-01 / Int Immunopharmacol 2022 Sep;110:1090162022-08-01 00:00:002022-08-01 00:00:00Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-25 / Epigenomics 2022 Jul;14(14):865-886
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-25 / Epigenomics 2022 Jul;14(14):865-8862022-07-25 00:00:002022-07-25 00:00:00Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy
